GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (FRA:4OR1) » Definitions » Total Inventories

Organovo Holdings (FRA:4OR1) Total Inventories : €0.58 Mil (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Organovo Holdings Total Inventories?

Organovo Holdings's total inventories for the quarter that ended in Sep. 2024 was €0.58 Mil. Organovo Holdings's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was €0.48 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Organovo Holdings's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was €0.03.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Organovo Holdings's Days Inventory for the three months ended in Sep. 2024 was 43,617.50.

Inventory Turnover measures how fast the company turns over its inventory within a year. Organovo Holdings's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Organovo Holdings's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 17.70.


Organovo Holdings Total Inventories Historical Data

The historical data trend for Organovo Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organovo Holdings Total Inventories Chart

Organovo Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.27

Organovo Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.27 0.38 0.58

Organovo Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Organovo Holdings  (FRA:4OR1) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Organovo Holdings's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is

Net-Net Working Capital Per Share (Q: Sep. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(2.86+0.75 * 0.026+0.5 * 0.577-2.77
-0-0)/15.3658
=0.03

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Organovo Holdings's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2024 )/Cost of Goods Sold (Q: Sep. 2024 )*Days in Period
=0.478/0.001*365 / 4
=43,617.50

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Organovo Holdings's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2024 ) / Average Total Inventories (Q: Sep. 2024 )
=0.001 / 0.478
=0.00

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Organovo Holdings's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=0.478 / 0.027
=17.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Organovo Holdings Total Inventories Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Organovo Holdings Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.

Organovo Holdings Headlines

No Headlines